Harmony Biosciences logo
Harmony Biosciences
HRMY | NASDAQ
Chart Builder DCF Calculator
$32.96
-$0.80 (-2.37%)
At close: Nov 16, 2026, 4:00 PM ET
$32.96
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Harmony Biosciences Company Profile

Company profile explained

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Key Executives

Name Position
Jeffrey Dayno President, Chief Executive Officer & Director
Peter Anastasiou Chief Operating Officer
Adam Zaeske Executive Vice President & Chief Commercial Officer
Andrew Serafin Executive Vice President & Chief Strategy Officer
Audrey Murphy Chief Human Resources Officer
Brennan Doyle Vice President & Head of Investor Relations
Christian Ulrich Executive VP, General Counsel & Corporate Secretary
Jeffrey S. Aronin Founder & Non-Executive Chairman
Kumar Budur Executive Vice President and Chief Medical & Scientific Officer
Stephen Mollichella Senior VP, Controller & Interim Principal Financial Officer
Tricia Glover Chief Compliance Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 8-K/A [Amend] Current Report
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 13, 2026 8-K Current Report
Sep 18, 2026 4 Filing
Sep 09, 2026 4 Filing
Aug 04, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jul 31, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 22, 2026 3 Filing
View All SEC Filings ➞
Harmony Biosciences
Harmony Biosciences logo
Country United States
IPO Date Aug 19, 2020
Industry Biotechnology
Sector Healthcare
Employees 293
CEO Jeffrey Dayno

Contact Details

630 West Germantown Pike Plymouth Meeting, Pennsylvania 19462 United States

Stock Details

Ticker Symbol HRMY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001802665
CUSIP Number 413197104
ISIN Number US4131971040
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.